Providing progressive cancer treatment and compassionate care.

Cancer News – 2018

  • Clinical Trial Shows Best Outcomes to Date for Older Hodgkin Lymphoma Patients

    Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy, which is the standard of care. Causes of poor outcomes for older Hodgkin lymphoma patients are not well … Continue reading "Clinical Trial Shows Best Outcomes to Date for Older Hodgkin Lymphoma Patients" […]

  • First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain

    Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, TX – September 13, 2018 – In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized … Continue reading "First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain" […]

  • Targeted Combination Treatment for Melanoma now Available

    The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. About Braftovi + Mektovi (encorafenib) is an oral small molecule BRAF kinase inhibitor and Mektovi (binimetinib) is an oral small … Continue reading "Targeted Combination Treatment for Melanoma now Available" […]

  • AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer

    PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) plus rituximab (RITUXAN®) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM), a rare and incurable type of … Continue reading "AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer" […]

  • Immune-mediated Nephritis Reported to Occur with Tecentriq®

    Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction.  The assessment was based on evaluation of approximately 17,215 clinical trial patients and 20,783 post-marketing patients that have been exposed to … Continue reading "Immune-mediated Nephritis Reported to Occur with Tecentriq®" […]

  • About The National Ovarian Cancer Coalition

    Where do you go when you’re first delivered the news: “You have cancer”? For many women diagnosed with ovarian cancer, the answer is the National Ovarian Cancer Coalition (NOCC). With more than 80 chapters nationwide, a Web site (www.ovarian.org) that includes active message boards, educational booklets, and a toll-free helpline, the organization is prepared to … Continue reading "About The National Ovarian Cancer Coalition" […]

  • Opdivo® (nivolumab) Approved for Treatment of Small Cell Lung Cancer

    The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.1 About Small Cell Lung Cancer According to the American Cancer Society, more than 234,000 people will be diagnosed with … Continue reading "Opdivo® (nivolumab) Approved for Treatment of Small Cell Lung Cancer" […]

  • FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer

    The U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This approval was based on results from REFLECT, where LENVIMA demonstrated a proven treatment effect on overall survival as well as statistically significant superiority and clinically meaningful improvements in progression-free survival … Continue reading "FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer" […]

  • Melanoma Linked with CLL, Wilmot Recommends Close Monitoring

    While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. Although a higher risk of melanoma had been known, a full analysis of detection … Continue reading "Melanoma Linked with CLL, Wilmot Recommends Close Monitoring" […]

  • FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors

    The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and other tissue areas. About Pheochromocytoma and Paraganglioma Pheochromocytomas and paragangliomas are rare neuroendocrine tumors that arise from cells of the sympathetic nervous system. When pheochromocytomas … Continue reading "FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors" […]